Reversible Posterior Encephalopathy Syndrome Secondary to Sunitinib | Zendy

Ricardo Costa | Zendy; Rubens Costa | Zendy; Rogerio de Souza Costa | Zendy; Gilberto Moura de Brito | Zendy; Henrique Cartaxo | Zendy; Alex Caetano de Barros | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reversible Posterior Encephalopathy Syndrome Secondary to Sunitinib

Author(s) -

Ricardo Costa,

Rubens Costa,

Rogerio de Souza Costa,

Gilberto Moura de Brito,

Henrique Cartaxo,

Alex Caetano de Barros

Publication year - 2014

Publication title -

case reports in oncological medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.173

H-Index - 7

eISSN - 2090-6714

pISSN - 2090-6706

DOI - 10.1155/2014/952624

Subject(s) - sunitinib , medicine , posterior reversible encephalopathy syndrome , renal cell carcinoma , hypertensive encephalopathy , cerebral edema , edema , vascular endothelial growth factor , oncology , magnetic resonance imaging , vegf receptors , radiology , blood pressure

Reversible posterior leukoencephalopathy syndrome (RPLS) is clinical radiologic condition associated with neurological symptoms and cerebral white matter edema. It has been associated with uncontrolled hypertension, eclampsia, immunosuppressants, and more recently the use of antiangiogenic drugs. Sunitinib is an inhibitor of the vascular endothelial growth factor receptor widely used in the treatment of metastatic renal cell carcinoma (RCC). We report a rare case of RPLS occurring on therapy with sunitinib in a patient with RCC. Our aim is to highlight the importance of considering RPLS as a diagnostic possibility and to hold sunitinib for RCC patients presenting with neurologic symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research